

# Darren K McGuire

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/546379/darren-k-mcguire-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

426  
papers

36,166  
citations

75  
h-index

186  
g-index

486  
ext. papers

47,190  
ext. citations

9.8  
avg, IF

7.33  
L-index

#	Paper	IF	Citations
426	Prediction of procedural success of transcatheter mitral valve repair with normal and extended clip arms.. <i>International Journal of Cardiovascular Imaging</i> , <b>2022</b> , 1	2.5	0
425	The year in cardiovascular medicine 2021: diabetes and metabolic disorders.. <i>European Heart Journal</i> , <b>2022</b> ,	9.5	2
424	Celebrating The Next Generation of Cardiovascular Investigators.. <i>Circulation</i> , <b>2022</b> , 145, 91-93	16.7	
423	Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58.. <i>Diabetes Care</i> , <b>2022</b> , 45, e27-e29	14.6	1
422	Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk.. <i>Cardiovascular Diabetology</i> , <b>2022</b> , 21, 12	8.7	0
421	Feasibility of Wearable-Based Remote Monitoring in Patients During Intensive Treatment for Aggressive Hematologic Malignancies.. <i>JCO Clinical Cancer Informatics</i> , <b>2022</b> , 6, e2100126	5.2	1
420	The gut hormone glucose-dependent insulinotropic polypeptide is downregulated in response to myocardial injury.. <i>Cardiovascular Diabetology</i> , <b>2022</b> , 21, 18	8.7	
419	Mannose as a biomarker of coronary artery disease: Angiographic evidence and clinical significance. <i>International Journal of Cardiology</i> , <b>2022</b> , 346, 86-92	3.2	1
418	Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e2148030	10.4	3
417	Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.. <i>Nature Medicine</i> , <b>2022</b> ,	50.5	9
416	Glucose-derived posttranslational modification in cardiovascular disease.. <i>Molecular Aspects of Medicine</i> , <b>2022</b> , 101084	16.7	0
415	Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling.. <i>Journal of Cardiovascular Translational Research</i> , <b>2022</b> , 1	3.3	1
414	Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter].. <i>Diabetologia</i> , <b>2022</b> , 65, 908	10.3	
413	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.. <i>Cardiovascular Diabetology</i> , <b>2022</b> , 21, 50	8.7	1
412	Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes - Data from a randomized, placebo-controlled study.. <i>Bone Reports</i> , <b>2022</b> , 16, 101175	2.6	0
411	Efficacy and Safety of ELOM-080 as Add-On Therapy in COVID-19 Patients with Acute Respiratory Insufficiency: Exploratory Data from the Prospective Placebo-Controlled COVARI Trial.. <i>Advances in Therapy</i> , <b>2022</b> , 1	4.1	
410	Sodium-glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 diabetes: A Meta-analysis of Individual Participant Data from Randomized Controlled Trials.. <i>Circulation</i> , <b>2022</b> ,	16.7	8

409	Guideline Development for Medical Device Technology: Issues for Consideration.. <i>Journal of Diabetes Science and Technology</i> , <b>2022</b> , 19322968221093355	4.1	
408	The Role of Vitamin D3 as an Independent Predicting Marker for One-Year Mortality in Patients with Acute Heart Failure. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11, 2733	5.1	1
407	Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison.. <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 1849-1857	15.1	0
406	2022 Beijing Winter Olympics: Spotlight on Cardiac Metabolism. <i>Circulation</i> , <b>2022</b> , 145, 1561-1562	16.7	
405	Platelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2021</b> ,	6.9	5
404	Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	2
403	Interpreting Absolute and Relative Risk Reduction in the Context of Recent Cardiovascular Outcome Trials in Patients with Type 2 Diabetes. <i>Current Diabetes Reports</i> , <b>2021</b> , 21, 45	5.6	0
402	Carbamylated sortilin associates with cardiovascular calcification in patients with chronic kidney disease. <i>Kidney International</i> , <b>2021</b> ,	9.9	6
401	Non-targeted metabolomics identify polyamine metabolite acisoga as novel biomarker for reduced left ventricular function. <i>ESC Heart Failure</i> , <b>2021</b> ,	3.7	1
400	A systematic review and meta-analysis of murine models of uremic cardiomyopathy. <i>Kidney International</i> , <b>2021</b> ,	9.9	2
399	Late outcome, therapy and systemic ventricular function in patients with a systemic right ventricle: data of the German National Register for Congenital Heart Defects. <i>Cardiology in the Young</i> , <b>2021</b> , 1-11	1	0
398	Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation. <i>Basic Research in Cardiology</i> , <b>2021</b> , 116, 57	11.8	3
397	Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1587-1598	15.1	3
396	Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. <i>Diabetes Care</i> , <b>2021</b> ,	14.6	2
395	Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1026-1036	12.3	16
394	Gut-Derived Metabolite Indole-3-Propionic Acid Modulates Mitochondrial Function in Cardiomyocytes and Alters Cardiac Function. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 648259	4.9	11
393	Time on previous renal replacement therapy is associated with worse outcomes of COVID-19 in a regional cohort of kidney transplant and dialysis patients. <i>Medicine (United States)</i> , <b>2021</b> , 100, e24893	1.8	3
392	Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. <i>Diabetologia</i> , <b>2021</b> , 64, 1256-1267	10.3	28

391	Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. <i>Diabetes Care</i> , <b>2021</b> , 44, 1159-1167	14.6	7
390	Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. <i>Circulation</i> , <b>2021</b> , 143, 1157-1172	16.7	130
389	Positioning newer drugs in the management of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> , 9, 139-140	18.1	1
388	Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes. <i>Diabetes Care</i> , <b>2021</b> , 44, 1236-1241	14.6	12
387	Development and validation of optimal phenomapping methods to estimate long-term atherosclerotic cardiovascular disease risk in patients with type 2 diabetes. <i>Diabetologia</i> , <b>2021</b> , 64, 1583-1594	10.3	5
386	Biomarker-Based Risk Prediction of Incident Heart Failure in Pre-Diabetes and Diabetes. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 215-223	7.9	12
385	Loss of CASK Accelerates Heart Failure Development. <i>Circulation Research</i> , <b>2021</b> , 128, 1139-1155	15.7	5
384	Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits. <i>Journal of Pharmaceutical Policy and Practice</i> , <b>2021</b> , 14, 35	3.2	
383	Proof of Concept: Measuring Aortic Annulus Resistance by Means of Pressure-Volume Curves During Balloon Inflation to Guide Transcatheter Aortic Valve Implantation. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 665029	5.4	0
382	Quantitative Flow Ratio Is Related to Intraluminal Coronary Stenosis Parameters as Assessed with Optical Coherence Tomography. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	2
381	Thromboembolic and Bleeding Events in COVID-19 Patients receiving Extracorporeal Membrane Oxygenation. <i>Thoracic and Cardiovascular Surgeon</i> , <b>2021</b> , 69, 526-536	1.6	9
380	Timely and individualized heart failure management: need for implementation into the new guidelines. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 110, 1150-1158	6.1	3
379	Coronary plaque composition influences biomechanical stress and predicts plaque rupture in a morpho-mechanic OCT analysis. <i>ELife</i> , <b>2021</b> , 10,	8.9	6
378	Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 2366-2377	15.1	2
377	Platelet Function in CKD: A Systematic Review and Meta-Analysis. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2021</b> ,	12.7	6
376	Six Months Follow-Up of Patients with Invasive Mechanical Ventilation due to COVID-19 Related ARDS. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6	6
375	Elevated serum SDMA and ADMA at hospital admission predict in-hospital mortality of COVID-19 patients. <i>Scientific Reports</i> , <b>2021</b> , 11, 9895	4.9	6
374	ACE2 polymorphism and susceptibility for SARS-CoV-2 infection and severity of COVID-19. <i>Pharmacogenetics and Genomics</i> , <b>2021</b> , 31, 165-171	1.9	20

373	Incidence and clinical relevance of persistent iatrogenic atrial septal defect after percutaneous mitral valve repair. <i>Scientific Reports</i> , <b>2021</b> , 11, 12700	4.9	0
372	Kidney outcomes using a sustained $\geq 40\%$ decline in eGFR: A meta-analysis of SGLT2 inhibitor trials. <i>Clinical Cardiology</i> , <b>2021</b> , 44, 1139-1143	3.3	6
371	Human and mouse non-targeted metabolomics identify 1,5-anhydroglucitol as SGLT2-dependent glycemetic marker. <i>Clinical and Translational Medicine</i> , <b>2021</b> , 11, e470	5.7	3
370	Outcomes of Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome in COVID-19 Patients: A Propensity-Matched Analysis. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	3
369	Treating heart failure in patients with diabetes: The view of the cardiologist. <i>Diabetes Research and Clinical Practice</i> , <b>2021</b> , 176, 108852	7.4	1
368	Accuracy of dynamic three-dimensional magnetic resonance perfusion imaging for the detection of coronary artery disease in patients with reduced ejection fraction. <i>Imaging</i> , <b>2021</b> , 13, 61-68	0.3	
367	Broncho-alveolar lavage in patients with acute respiratory distress syndrome due to COVID-19. <i>Internal Medicine Journal</i> , <b>2021</b> , 51, 965-967	1.6	1
366	Lesion Geometry as Assessed by Optical Coherence Tomography Is Related to Myocardial Ischemia as Determined by Cardiac Magnetic Resonance Imaging. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
365	Quantitative flow ratio (QFR) identifies functional relevance of non-culprit lesions in coronary angiographies of patients with acute myocardial infarction. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 110, 1659-1667	6.1	2
364	Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. <i>Circulation</i> , <b>2021</b> , 144, 74-84	16.7	9
363	Nicotine promotes vascular calcification via intracellular Ca <sup>2+</sup> -mediated, Nox5-induced oxidative stress and extracellular vesicle release in vascular smooth muscle cells. <i>Cardiovascular Research</i> , <b>2021</b> ,	9.9	2
362	The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. <i>Diabetes Care</i> , <b>2021</b> , 44, 1805-1815	14.6	10
361	Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1260-1275	12.3	12
360	Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA <sup>2</sup> trial. <i>Diabetology International</i> , <b>2021</b> , 12, 87-100	2.3	5
359	Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> , 9, 46-52	18.1	34
358	Screen-detected atrial fibrillation predicts mortality in elderly subjects. <i>Europace</i> , <b>2021</b> , 23, 29-38	3.9	11
357	Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 148-158	16.2	194
356	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 117-128	59.2	408

355	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 129-139	59.2	243
354	Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function: Observations From VERTIS CV. <i>Circulation</i> , <b>2021</b> , 143, 602-605	16.7	11
353	Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 569-580	6.7	7
352	Role of extracorporeal membrane oxygenation in critically ill COVID-19 patients and predictors of mortality. <i>Artificial Organs</i> , <b>2021</b> , 45, E158-E170	2.6	18
351	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. <i>Circulation</i> , <b>2021</b> , 143, 337-349	16.7	80
350	SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , <b>2021</b> , 77, 94-109	7.4	27
349	Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults With Diabetes. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 354-357	16.2	3
348	SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>Diabetes</i> , <b>2021</b> , 70, 1-16	0.9	18
347	Dynamic handgrip exercise for the evaluation of mitral valve regurgitation: an echocardiographic study to identify exertion induced severe mitral regurgitation. <i>International Journal of Cardiovascular Imaging</i> , <b>2021</b> , 37, 891-902	2.5	0
346	Lactic acidosis incidence with metformin in patients with type 2 diabetes and chronic kidney disease: A retrospective nested case-control study. <i>Endocrinology, Diabetes and Metabolism</i> , <b>2021</b> , 4, e00170	2.7	3
345	Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 29-38	6.7	11
344	Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin Study. <i>Diabetes Technology and Therapeutics</i> , <b>2021</b> , 23, 59-69	8.1	3
343	Antihyperglycemic therapies and cardiovascular outcomes in patients with type 2 diabetes mellitus: State of the art and future directions. <i>Trends in Cardiovascular Medicine</i> , <b>2021</b> , 31, 101-108	6.9	2
342	Gaps in Evidence-Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e016835	6	11
341	Early risk markers for severe clinical course and fatal outcome in German patients with COVID-19. <i>PLoS ONE</i> , <b>2021</b> , 16, e0246182	3.7	4
340	Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. <i>CKJ: Clinical Kidney Journal</i> , <b>2021</b> , 14, 226-236	4.5	1
339	Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke. <i>Journal of Hypertension</i> , <b>2021</b> , 39, 1602-1610	1.9	0
338	The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. <i>Diabetologia</i> , <b>2021</b> , 64, 1226-1234	10.3	4

337	Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. <i>European Journal of Preventive Cardiology</i> , <b>2021</b> ,	3.9	7
336	Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. <i>Journal of Hypertension</i> , <b>2021</b> , 39, 766-774	1.9	2
335	Association of Glucose-Dependent Insulinotropic Polypeptide Levels With Cardiovascular Mortality in Patients With Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e019477	6.7	2
334	Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. <i>Diabetes Research and Clinical Practice</i> , <b>2021</b> , 177, 108870	7.4	1
333	Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study. <i>Atherosclerosis</i> , <b>2021</b> , 330, 8-13	3.1	1
332	Association Between Achieved $\beta$ Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial. <i>JAMA Cardiology</i> , <b>2021</b> ,	16.2	13
331	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 1065-1072	8	6
330	Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2814-2818	6.7	4
329	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 1451-1461	59.2	358
328	Epigenetic Clocks Are Not Accelerated in COVID-19 Patients. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	7
327	Quantitative Flow Ratio Is Associated with Extent and Severity of Ischemia in Non-Culprit Lesions of Patients with Myocardial Infarction. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
326	Syncope in a Middle-aged Man: A Revealing Electrocardiogram. <i>JAMA Internal Medicine</i> , <b>2021</b> , 181, 1505-1506	15.6	0
325	In Vivo Study of Electromagnetic Interference With Cardiac Contractility Modulation Devices at Power Frequency. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e019171	6	
324	GLP1 receptor agonists: from antihyperglycaemic to cardiovascular drugs. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> , 9, 640-641	18.1	
323	Clinical course of COVID-19 patients needing supplemental oxygen outside the intensive care unit. <i>Scientific Reports</i> , <b>2021</b> , 11, 2256	4.9	14
322	Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study. <i>Cardiovascular Diabetology</i> , <b>2021</b> , 20, 6	8.7	13
321	Extracorporeal membrane oxygenation in patients with COVID-19: 1-year experience. <i>Journal of Thoracic Disease</i> , <b>2021</b> , 13, 5911-5924	2.6	0
320	Association of Long-term Change and Variability in Glycemia With Risk of Incident Heart Failure Among Patients With Type 2 Diabetes: A Secondary Analysis of the ACCORD Trial. <i>Diabetes Care</i> , <b>2020</b> , 43, 1920-1928	14.6	14

319	Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 1182-1190	16.2	27
318	Cross-omics analysis revealed gut microbiome-related metabolic pathways underlying atherosclerosis development after antibiotics treatment. <i>Molecular Metabolism</i> , <b>2020</b> , 36, 100976	8.8	26
317	Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial. <i>Circulation</i> , <b>2020</b> , 141, 1295-1306	16.7	35
316	Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis. <i>European Journal of Haematology</i> , <b>2020</b> , 105, 655-658	3.8	13
315	Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial. <i>Diabetes Care</i> , <b>2020</b> , 43, e108-e110	14.6	17
314	Response to Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. <i>Diabetes Care</i> 2019;42:2298-2306. <i>Diabetes Care</i> , <b>2020</b> , 43, e26-e27	14.6	1
313	Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2026-2034	12.3	9
312	Segmental Bioelectrical Impedance Spectroscopy to Monitor Fluid Status in Heart Failure. <i>Scientific Reports</i> , <b>2020</b> , 10, 3577	4.9	11
311	Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1122-1131	6.7	13
310	Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. <i>Circulation</i> , <b>2020</b> , 141, 1227-1234	16.7	97
309	Response by Bergmark et al to Letter Regarding Article, "Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial". <i>Circulation</i> , <b>2020</b> , 141, e57-e58	16.7	1
308	Trimethylamine N-Oxide and Adenosine Diphosphate-Induced Platelet Reactivity Are Independent Risk Factors for Cardiovascular and All-Cause Mortality. <i>Circulation Research</i> , <b>2020</b> , 126, 660-662	15.7	2
307	Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions. <i>Circulation</i> , <b>2020</b> , 141, 843-862	16.7	25
306	Empagliflozin improves left ventricular diastolic function of db/db mice. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2020</b> , 1866, 165807	6.9	15
305	Sharp rises in FGF23 and hypophosphatemia after intravenous iron administration do not cause myocardial damage. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 1316-1318	6.1	2
304	Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. <i>American Journal of Cardiology</i> , <b>2020</b> , 125, 1577-1581	15.81	1
303	Reduction of cardiovascular risk in patients with T2DM by GLP-1 receptor agonists: a shift in paradigm driven by data from large cardiovascular outcome trials. <i>European Heart Journal</i> , <b>2020</b> , 41, 3359-3362	9.5	4
302	Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1357-1368	6.7	13



301	Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN-6 cardiovascular outcomes trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1537-1547	6.7	22
300	Glucagon-like peptide 1 levels predict cardiovascular risk in patients with acute myocardial infarction. <i>European Heart Journal</i> , <b>2020</b> , 41, 882-889	9.5	11
299	Ivabradine for the Therapy of Chronic Stable Angina Pectoris: a Systematic Review and Meta-Analysis. <i>Korean Circulation Journal</i> , <b>2020</b> , 50, 773-786	2.2	0
298	Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. <i>Diabetes Care</i> , <b>2020</b> , 43, 1803-1812	14.6	20
297	Colocalization of plaque macrophages and calcification in coronary plaques as detected by optical coherence tomography predicts cardiovascular outcome. <i>Cardiology Journal</i> , <b>2020</b> , 27, 303-306	1.4	2
296	Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11). <i>Diabetes Therapy</i> , <b>2020</b> , 11, 53-70	3.6	12
295	Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS. <i>American Heart Journal</i> , <b>2020</b> , 219, 47-57	4.9	14
294	Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. <i>Diabetes Care</i> , <b>2020</b> , 43, 468-475	14.6	33
293	Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 126-135	12.3	30
292	Glycated Hemoglobin, Prediabetes, and the Links to Cardiovascular Disease: Data From UK Biobank. <i>Diabetes Care</i> , <b>2020</b> , 43, 440-445	14.6	24
291	Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. <i>Circulation</i> , <b>2020</b> , 142, 2205-2215	16.7	77
290	High cardiovascular risk of patients with type 2 diabetes is only partially attributed to angiographic burden of atherosclerosis. <i>Diabetes and Vascular Disease Research</i> , <b>2020</b> , 17, 1479164120953612	3.3	4
289	The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , <b>2020</b> , 43, 3007-3015	14.6	13
288	Integrative Multi-Omics Analysis in Calcific Aortic Valve Disease Reveals a Link to the Formation of Amyloid-Like Deposits. <i>Cells</i> , <b>2020</b> , 9,	7.9	7
287	Reliable Detection of Atrial Fibrillation with a Medical Wearable during Inpatient Conditions. <i>Sensors</i> , <b>2020</b> , 20,	3.8	5
286	Post-cardiac injury syndrome after transcatheter mitral valve repair using MitraClip system: a case report. <i>European Heart Journal - Case Reports</i> , <b>2020</b> , 4, 1-5	0.9	4
285	Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae. <i>Respiratory Medicine</i> , <b>2020</b> , 174, 106197	4.6	100
284	Car Seats with Capacitive ECG Electrodes Can Detect Cardiac Pacemaker Spikes. <i>Sensors</i> , <b>2020</b> , 20,	3.8	4

283	Diabetes and cardiovascular disease: it's time to apply the evidence. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2020</b> , 9, 586-588	4.3	
282	First-line treatment for type 2 diabetes: is it too early to abandon metformin?. <i>Lancet, The</i> , <b>2020</b> , 396, 1705-1707	4.0	9
281	Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. <i>Lancet Diabetes and Endocrinology, the</i> , <b>2020</b> , 8, 949-959	18.1	14
280	Prognostic irrelevance of plaque vulnerability following plaque sealing in high-risk patients with type 2 diabetes: an optical coherence tomography study. <i>Cardiovascular Diabetology</i> , <b>2020</b> , 19, 192	8.7	5
279	Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 324, 2268-2280	27.4	209
278	Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. <i>Circulation</i> , <b>2020</b> , 142, 734-747	16.7	16
277	Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2487-2492	6.7	11
276	Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. <i>Advanced Drug Delivery Reviews</i> , <b>2020</b> , 159, 4-33	18.5	23
275	Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist. <i>Current Cardiology Reports</i> , <b>2020</b> , 22, 105	4.2	1
274	Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME. <i>Journal of Hypertension</i> , <b>2020</b> , 38, 1829-1840	1.9	10
273	Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1425-1435	59.2	418
272	Two Tales: One Story: EMPEROR-Reduced and DAPA-HF. <i>Circulation</i> , <b>2020</b> , 142, 2201-2204	16.7	7
271	Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. <i>Circulation</i> , <b>2020</b> , 142, 1205-1218	16.7	16
270	Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies. <i>Diabetes Care</i> , <b>2020</b> , 43, 2713-2720	14.6	6
269	Medicaid Expansion and Utilization of Antihyperglycemic Therapies. <i>Diabetes Care</i> , <b>2020</b> , 43, 2684-2690	14.6	3
268	Prescribing Paradigm Shift? Damned If You Do, Damned If You Don't. <i>Diabetes Care</i> , <b>2020</b> , 43, 1991-1993	14.6	
267	Development of the Metabolic Syndrome: Study Design and Baseline Data of the Lufthansa Prevention Study (LUPS), A Prospective Observational Cohort Survey. <i>Experimental and Clinical Endocrinology and Diabetes</i> , <b>2020</b> , 128, 777-787	2.3	1
266	Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. <i>European Heart Journal</i> , <b>2020</b> , 41, 231-238	9.5	16

265	Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017. <i>JAMA Internal Medicine</i> , <b>2020</b> , 180, 141-144	11.5	14
264	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , <b>2020</b> , 41, 255-323	9.5	1360
263	Incidence and predictors of pacemaker induced cardiomyopathy: A single-center experience. <i>Journal of Electrocardiology</i> , <b>2019</b> , 57, 31-34	1.4	3
262	Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS. <i>Cardiovascular Diabetology</i> , <b>2019</b> , 18, 116	8.7	9
261	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , <b>2019</b> , 140, 1569-1577	16.7	57
260	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet, The</i> , <b>2019</b> , 394, 1169-1180	40	106
259	Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 322, 1155-1166	27.4	245
258	Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. <i>Circulation</i> , <b>2019</b> , 140, 1463-1476	16.7	163
257	Intrinsic calcification angle: a novel feature of the vulnerable coronary plaque in patients with type 2 diabetes: an optical coherence tomography study. <i>Cardiovascular Diabetology</i> , <b>2019</b> , 18, 122	8.7	12
256	International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. <i>American Heart Journal</i> , <b>2019</b> , 218, 57-65	4.9	3
255	FDA guidance on antihyperglycemic therapies for type 2 diabetes: One decade later. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1073-1078	6.7	27
254	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. <i>Lancet Diabetes and Endocrinology, the</i> , <b>2019</b> , 7, 606-617	18.1	304
253	Identifying Familial Hypercholesterolemia Using a Blood Donor Screening Program With More Than 1 Million Volunteer Donors. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 685-689	16.2	8
252	Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes. <i>International Journal of Cardiology</i> , <b>2019</b> , 289, 58-62	3.2	0
251	Significance of psychosocial factors in cardiology: update 2018 : Position paper of the German Cardiac Society. <i>Clinical Research in Cardiology</i> , <b>2019</b> , 108, 1175-1196	6.1	38
250	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. <i>Circulation</i> , <b>2019</b> , 139, 2516-2527	16.7	142
249	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. <i>Circulation</i> , <b>2019</b> , 139, 2528-2536	16.7	283
248	Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program. <i>Diabetes Care</i> , <b>2019</b> , 42, 919-930	14.6	37

247	Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. <i>European Heart Journal</i> , <b>2019</b> , 40, 2032-2043	9.5	23
246	Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1625-1633	6.7	14
245	Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10). <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1437-1444	6.7	9
244	A novel transcatheter aortic valve with a form-fitting anchor for self-alignment: feasibility in a chronic preclinical model. <i>Interactive Cardiovascular and Thoracic Surgery</i> , <b>2019</b> , 29, 8-14	1.8	
243	Relative Prognostic Importance and Optimal Levels of Risk Factors for Mortality and Cardiovascular Outcomes in Type 1 Diabetes Mellitus. <i>Circulation</i> , <b>2019</b> , 139, 1900-1912	16.7	49
242	Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 261-266	6.7	6
241	Whole-Body Plethysmography and Blood Gas Analysis in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. <i>Respiration</i> , <b>2019</b> , 97, 24-33	3.7	3
240	Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 3-14	6.7	29
239	Speckle Tracking Echocardiography and All-Cause and Cardiovascular Mortality Risk in Chronic Kidney Disease Patients. <i>Kidney and Blood Pressure Research</i> , <b>2019</b> , 44, 690-703	3.1	3
238	Long-term follow-up of intensive glycaemic control in type 2 diabetes. <i>Nature Reviews Cardiology</i> , <b>2019</b> , 16, 517-518	14.8	3
237	Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial. <i>Circulation</i> , <b>2019</b> , 140, 1004-1014	16.7	40
236	Novel plasma peptide markers involved in the pathology of CKD identified using mass spectrometric approach. <i>Journal of Molecular Medicine</i> , <b>2019</b> , 97, 1451-1463	5.5	5
235	Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2440-2449	6.7	15
234	Aerobic Fitness and Adherence to Guideline-Recommended Minimum Physical Activity Among Ambulatory Patients With Type 2 Diabetes Mellitus. <i>Diabetes Care</i> , <b>2019</b> , 42, 1333-1339	14.6	16
233	The Dallas Bed Rest and Training Study: Revisited After 50 Years. <i>Circulation</i> , <b>2019</b> , 140, 1293-1295	16.7	6
232	Associations between $\beta$ -blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease. <i>American Heart Journal</i> , <b>2019</b> , 218, 92-99	4.9	1
231	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. <i>Circulation</i> , <b>2019</b> , 139, 2022-2031	16.7	345
230	Cardiac FGF23: new insights into the role and function of FGF23 after acute myocardial infarction. <i>Cardiovascular Pathology</i> , <b>2019</b> , 40, 47-54	3.8	13

229	Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. <i>Diabetes Care</i> , <b>2019</b> , 42, 2298-2306	14.6	70
228	Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. <i>European Journal of Preventive Cardiology</i> , <b>2019</b> , 26, 73-80	3.9	39
227	Artificial intelligence supported patient self-care in chronic heart failure: a paradigm shift from reactive to predictive, preventive and personalised care. <i>EPMA Journal</i> , <b>2019</b> , 10, 445-464	8.8	47
226	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. <i>Circulation</i> , <b>2019</b> , 140, 2108-2118	16.7	13
225	Diabetes Mellitus and the Heart. <i>Experimental and Clinical Endocrinology and Diabetes</i> , <b>2019</b> , 127, S102-S104	1.04	2
224	Position Paper on Lipid Therapy in Patients with Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , <b>2019</b> , 127, S97-S101	2.3	
223	Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. <i>Circulation</i> , <b>2019</b> , 139, 351-361	16.7	103
222	Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 321, 69-79	27.4	562
221	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 347-357	59.2	2455
220	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. <i>Lancet, The</i> , <b>2019</b> , 393, 31-39	40	1300
219	Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. <i>Circulation</i> , <b>2019</b> , 139, 366-375	16.7	21
218	Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease. <i>Journal of Cardiac Failure</i> , <b>2019</b> , 25, 78-86	3.3	13
217	Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. <i>Circulation</i> , <b>2019</b> , 139, 1384-1395	16.7	115
216	Predictors for target lesion microcalcifications in patients with stable coronary artery disease: an optical coherence tomography study. <i>Clinical Research in Cardiology</i> , <b>2018</b> , 107, 763-771	6.1	19
215	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. <i>American Heart Journal</i> , <b>2018</b> , 200, 83-89	4.9	89
214	DECLARE-TIMI 58: Participants\baseline characteristics. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1102-1108	1108	0
213	Opportunities and challenges of large-scale screening for atrial fibrillation. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , <b>2018</b> , 29, 57-61	0.8	3
212	Rationale, design, and baseline characteristics of the Cardiovascular safety and Renal Microvascular outcome study with LINAGliptin (CARMELINA): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. <i>Cardiovascular Diabetology</i> , <b>2018</b> , 17, 89	8.7	57

211	Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. <i>American Heart Journal</i> , <b>2018</b> , 202, 39-48	4.9	12
210	The new SFB/TRR219 Research Centre. <i>European Heart Journal</i> , <b>2018</b> , 39, 975-977	9.5	5
209	Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 1379-1390	15.1	43
208	DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. <i>Diabetologia</i> , <b>2018</b> , 61, 58-65	10.3	98
207	Myocardial infarction is sufficient to increase GLP-1 secretion, leading to improved left ventricular contractility and mitochondrial respiratory capacity. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2911-2918	6.7	10
206	Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach. <i>Current Diabetes Reports</i> , <b>2018</b> , 18, 64	5.6	19
205	Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University. <i>Clinical Research in Cardiology</i> , <b>2018</b> , 107, 120-126	6.1	20
204	Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , <b>2018</b> , 138, 2315-2325	16.7	75
203	Glucagon-Like Peptide 1 and Its Cleavage Products Are Renoprotective in Murine Diabetic Nephropathy. <i>Diabetes</i> , <b>2018</b> , 67, 2410-2419	0.9	26
202	Reduced post-operative DPP4 activity associated with worse patient outcome after cardiac surgery. <i>Scientific Reports</i> , <b>2018</b> , 8, 11820	4.9	8
201	Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors. <i>JACC Basic To Translational Science</i> , <b>2018</b> , 3, 575-587	8.7	162
200	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1107-1117	59.2	143
199	Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR). <i>Journal of Diabetes and Its Complications</i> , <b>2018</b> , 32, 1035-1039	3.2	2
198	Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 633-644	59.2	518
197	Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. <i>Clinical Cardiology</i> , <b>2018</b> , 41, 1281-1288	3.3	134
196	SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases. <i>Diabetologia</i> , <b>2018</b> , 61, 2134-2139	10.3	32
195	Impact of multidrug-resistant bacteria on outcome in patients with prolonged weaning. <i>BMC Pulmonary Medicine</i> , <b>2018</b> , 18, 141	3.5	5
194	The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE mice by blocking monocyte/macrophage activation. <i>Molecular Metabolism</i> , <b>2018</b> , 14, 150-157	8.8	26

193	Adipose tissue ATGL modifies the cardiac lipidome in pressure-overload-induced left ventricular failure. <i>PLoS Genetics</i> , <b>2018</b> , 14, e1007171	6	24
192	Heart failure: an underestimated therapeutic target in diabetes. <i>Cardiovascular Endocrinology</i> , <b>2018</b> , 7, 10-12		2
191	Sclerostin deficiency modifies the development of CKD-MBD in mice. <i>Bone</i> , <b>2018</b> , 107, 115-123	4.7	15
190	Hyperkalaemia in Heart Failure-Pathophysiology, Implications and Therapeutic Perspectives. <i>Current Heart Failure Reports</i> , <b>2018</b> , 15, 390-397	2.8	8
189	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. <i>European Heart Journal</i> , <b>2018</b> , 39, 4243-4254	9.5	113
188	Endpunktstudien in der Diabetestherapie. <i>Diabetologe</i> , <b>2018</b> , 14, 376-383	0.2	
187	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. <i>Lancet, The</i> , <b>2018</b> , 392, 2269-2279	4.0	46
186	Co-localization of plaque macrophages with calcification is associated with a more vulnerable plaque phenotype and a greater calcification burden in coronary target segments as determined by OCT. <i>PLoS ONE</i> , <b>2018</b> , 13, e0205984	3.7	22
185	Design and baseline characteristics of the eValuation of ERTugliflozin efficacy and Safety CardioVascular outcomes trial (VERTIS-CV). <i>American Heart Journal</i> , <b>2018</b> , 206, 11-23	4.9	139
184	Relation of plasma ceramides to visceral adiposity, insulin resistance and the development of type 2 diabetes mellitus: the Dallas Heart Study. <i>Diabetologia</i> , <b>2018</b> , 61, 2570-2579	10.3	44
183	Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). <i>American Heart Journal</i> , <b>2018</b> , 203, 25-29	4.9	15
182	Pathways to Cardiorenal Complications in Type 2 Diabetes Mellitus: A Need to Rethink. <i>Circulation</i> , <b>2018</b> , 138, 7-9	16.7	21
181	Effects of sodium glucose co-transporter 2 inhibitors on the kidney. <i>Diabetes and Vascular Disease Research</i> , <b>2018</b> , 15, 375-386	3.3	24
180	HbA and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study. <i>Diabetes Care</i> , <b>2018</b> , 41, 1981-1990	14.6	95
179	Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. <i>Diabetes Care</i> , <b>2018</b> , 41, 1970-1980	14.6	117
178	Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2379-2388	6.7	15
177	Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 155-163	16.2	49
176	Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). <i>Diabetes Care</i> , <b>2017</b> , 40, 494-501	14.6	40

175	The association between HDL particle concentration and incident metabolic syndrome in the multi-ethnic Dallas Heart Study. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , <b>2017</b> , 11 Suppl 1, S175-S179	8.9	10
174	Sex-Based Differences in Cardiometabolic Biomarkers. <i>Circulation</i> , <b>2017</b> , 135, 544-555	16.7	82
173	Atrial Fibrillation, Type 2 Diabetes, and Non-Vitamin K Antagonist Oral Anticoagulants: A Review. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 442-448	16.2	39
172	Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2017</b> , 5, 391-402	18.1	42
171	A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes. <i>Cardiovascular Diabetology</i> , <b>2017</b> , 16, 13	8.7	26
170	Range of Risk Factor Levels: Control, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes Mellitus. <i>Circulation</i> , <b>2017</b> , 135, 1522-1531	16.7	61
169	In Vivo Study of Electromagnetic Interference With Pacemakers Caused by Everyday Electric and Magnetic Fields. <i>Circulation</i> , <b>2017</b> , 135, 907-909	16.7	14
168	Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1407-1418	59.2	563
167	Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin). <i>Circulation</i> , <b>2017</b> , 136, 1193-1203	16.7	33
166	Longitudinal changes in serum 25-hydroxyvitamin D in the Dallas Heart Study. <i>Clinical Endocrinology</i> , <b>2017</b> , 87, 242-248	3.4	11
165	Slower Progress of Aortic Valve Calcification With Vitamin K Supplementation: Results From a Prospective Interventional Proof-of-Concept Study. <i>Circulation</i> , <b>2017</b> , 135, 2081-2083	16.7	75
164	Diabetes Mellitus and Heart Failure. <i>American Journal of Medicine</i> , <b>2017</b> , 130, S40-S50	2.4	77
163	Circulating annexin A5 levels are associated with carotid intima-media thickness but not coronary plaque composition. <i>Diabetes and Vascular Disease Research</i> , <b>2017</b> , 14, 415-422	3.3	1
162	Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 723-732	59.2	349
161	Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort. <i>Clinical Cardiology</i> , <b>2017</b> , 40, 899-906	3.3	2
160	Diabetes Mellitus and Heart Failure. <i>American Journal of Cardiology</i> , <b>2017</b> , 120, S37-S47	3	98
159	GLP-1 Levels Predict Mortality in Patients with Critical Illness as Well as End-Stage Renal Disease. <i>American Journal of Medicine</i> , <b>2017</b> , 130, 833-841.e3	2.4	30
158	Corrections needed to 2016 ESC and AHA guidelines on heart failure. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2017</b> , 5, 325-326	18.1	6



157	Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization. <i>American Heart Journal</i> , <b>2017</b> , 188, 156-166	4.9	8
156	Multimodality Strategy for Cardiovascular Risk Assessment: Performance in 2 Population-Based Cohorts. <i>Circulation</i> , <b>2017</b> , 135, 2119-2132	16.7	51
155	The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 496-508	6.7	16
154	QT prolongation caused by insulin-induced hypoglycaemia - An interventional study in 119 individuals. <i>Diabetes Research and Clinical Practice</i> , <b>2017</b> , 123, 165-172	7.4	18
153	Unobtrusive Nocturnal Heartbeat Monitoring by a Ballistocardiographic Sensor in Patients with Sleep Disordered Breathing. <i>Scientific Reports</i> , <b>2017</b> , 7, 13175	4.9	19
152	Type 2 diabetes mellitus is associated with a lower fibrous cap thickness but has no impact on calcification morphology: an intracoronary optical coherence tomography study. <i>Cardiovascular Diabetology</i> , <b>2017</b> , 16, 152	8.7	36
151	Electrical impedance tomography for predicting failure of spontaneous breathing trials in patients with prolonged weaning. <i>Critical Care</i> , <b>2017</b> , 21, 177	10.8	19
150	Transcatheter aortic valve-in-valve implantation of a CoreValve in a JenaValve prosthesis: a case report. <i>Journal of Medical Case Reports</i> , <b>2017</b> , 11, 256	1.2	2
149	quantification of amyloid burden in TTR-related cardiac amyloidosis. <i>Intractable and Rare Diseases Research</i> , <b>2017</b> , 6, 291-294	1.4	1
148	Effect of lead position and orientation on electromagnetic interference in patients with bipolar cardiovascular implantable electronic devices. <i>Europace</i> , <b>2017</b> , 19, 319-328	3.9	11
147	The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1390-1400	12.3	111
146	Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?. <i>Diabetes Care</i> , <b>2017</b> , 40, 1144-1151	14.6	30
145	Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin. <i>Hypertension</i> , <b>2017</b> , 70, 907-914	8.5	10
144	Residual Angina After Elective Percutaneous Coronary Intervention in Patients With Diabetes Mellitus. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2017</b> , 10,	5.8	6
143	Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 2337-2348	59.2	224
142	Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	14
141	Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease. <i>Circulation</i> , <b>2017</b> , 136, 969-972	16.7	75
140	Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR Research to Practice project. <i>European Journal of Preventive Cardiology</i> , <b>2017</b> , 24, 1637-1645	3.9	73

139	Multi-centre study of whole-heart dynamic 3D cardiac magnetic resonance perfusion imaging for the detection of coronary artery disease defined by fractional flow reserve: gender based analysis of diagnostic performance. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2017</b> , 18, 1099-1106	4.1	6
138	Intra-procedural determination of viability by myocardial deformation imaging: a randomized prospective study in the cardiac catheter laboratory. <i>Clinical Research in Cardiology</i> , <b>2017</b> , 106, 629-644	6.1	2
137	Major Bleeding in Patients With Diabetes and Atrial Fibrillation Treated With New Oral Anticoagulants-Reply. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 1168	16.2	3
136	Internet-based training of coronary artery patients: the Heart Cycle Trial. <i>Heart and Vessels</i> , <b>2017</b> , 32, 408-418	2.1	27
135	Impact of empagliflozin in patients with diabetes and heart failure. <i>Trends in Cardiovascular Medicine</i> , <b>2017</b> , 27, 144-151	6.9	12
134	Trimethylamine-N-oxide and Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 3202-3204	15.1	38
133	Diabetes medications and cardiovascular outcome trials: Lessons learned. <i>Cleveland Clinic Journal of Medicine</i> , <b>2017</b> , 84, 759-767	2.8	11
132	Epicardial adipose tissue in long-term hemodialysis patients: its association with vascular calcification and long-term development. <i>Journal of Nephrology</i> , <b>2016</b> , 29, 241-250	4.8	11
131	The vulnerable patient with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , <b>2016</b> , 31, 382-90	4.3	24
130	A Test in Context: Hemoglobin A and Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 2479-2486	15.1	15
129	Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. <i>Diabetes Care</i> , <b>2016</b> , 39, 2304-2310	14.6	114
128	Predicting Adverse Outcomes After Myocardial Infarction Among Patients With Diabetes Mellitus. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2016</b> , 9, 372-9	5.8	17
127	Effect of treatment with rosiglitazone on high-sensitivity cardiac troponin levels among patients with type 2 diabetes mellitus. <i>Diabetes and Vascular Disease Research</i> , <b>2016</b> , 13, 113-8	3.3	3
126	Interleukin-6 predicts inflammation-induced increase of Glucagon-like peptide-1 in humans in response to cardiac surgery with association to parameters of glucose metabolism. <i>Cardiovascular Diabetology</i> , <b>2016</b> , 15, 21	8.7	27
125	Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. <i>Circulation</i> , <b>2016</b> , 133, e38-360	16.7	4504
124	A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 393-402	4.1	9
123	Prediction of Outcomes in Patients with Chronic Ischemic Cardiomyopathy by Layer-Specific Strain Echocardiography: A Proof of Concept. <i>Journal of the American Society of Echocardiography</i> , <b>2016</b> , 29, 412-20	5.8	35
122	Glycaemic control and cardiovascular risk factor management in patients with diabetes with and without coronary artery disease: insights from the diabetes mellitus status in Canada survey. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , <b>2016</b> , 2, 277-284	4.6	12

121	Association of Body Mass Index With Care and Outcomes in Patients With Atrial Fibrillation: Results From the ORBIT-AF Registry. <i>JACC: Clinical Electrophysiology</i> , <b>2016</b> , 2, 355-363	4.6	32
120	Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. <i>Diabetes and Vascular Disease Research</i> , <b>2016</b> , 13, 119-26	3.3	94
119	Myocardial deformation by strain echocardiography identifies patients with acute coronary syndrome and non-diagnostic ECG presenting in a chest pain unit: a prospective study of diagnostic accuracy. <i>Clinical Research in Cardiology</i> , <b>2016</b> , 105, 248-56	6.1	21
118	Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. <i>American Journal of Medicine</i> , <b>2016</b> , 129, 340.e1-8	2.4	27
117	Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. <i>Circulation Research</i> , <b>2016</b> , 118, 1830-43	15.7	46
116	Microdialysis and proteomics of subcutaneous interstitial fluid reveals increased galectin-1 in type 2 diabetes patients. <i>Metabolism: Clinical and Experimental</i> , <b>2016</b> , 65, 998-1006	12.7	13
115	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2016</b> , 1, 126-35	16.2	161
114	Revascularization Trends in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting With Non-ST Elevation Myocardial Infarction: Insights From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with the Guidelines (NCDR-ACTION Registry-GWTG). <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2016</b> , 9, e004000	5.8	33
113	Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. <i>European Heart Journal</i> , <b>2016</b> , 37, 3192-3200	9.5	117
112	Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1. <i>American Heart Journal</i> , <b>2016</b> , 179, 175-83	4.9	51
111	Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy. <i>American Heart Journal</i> , <b>2016</b> , 182, 111-118	4.9	9
110	State-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus. <i>Current Cardiovascular Risk Reports</i> , <b>2015</b> , 9, 4	0.9	11
109	Metabolic Effects of Exercise Training Among Fitness-Nonresponsive Patients With Type 2 Diabetes: The HART-D Study. <i>Diabetes Care</i> , <b>2015</b> , 38, 1494-501	14.6	49
108	Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial. <i>American Heart Journal</i> , <b>2015</b> , 170, 753-759.e2	4.9	5
107	Are patients with cardiac implants protected against electromagnetic interference in daily life and occupational environment?. <i>European Heart Journal</i> , <b>2015</b> , 36, 1798-804	9.5	26
106	Design and baseline characteristics of the CARDiovascular Outcome Trial of LINAgliptin Versus Glimperide in Type 2 Diabetes (CAROLINA). <i>Diabetes and Vascular Disease Research</i> , <b>2015</b> , 12, 164-74	3.3	182
105	Recognition of incident diabetes mellitus during an acute myocardial infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2015</b> , 8, 260-7	5.8	13
104	Multicenter evaluation of dynamic three-dimensional magnetic resonance myocardial perfusion imaging for the detection of coronary artery disease defined by fractional flow reserve. <i>Circulation: Cardiovascular Imaging</i> , <b>2015</b> , 8,	3.9	43

103	Identification of the Vasoconstriction-Inhibiting Factor (VIF), a Potent Endogenous Cofactor of Angiotensin II Acting on the Angiotensin II Type 2 Receptor. <i>Circulation</i> , <b>2015</b> , 131, 1426-34	16.7	30
102	Serum levels of C-peptide are associated with coronary artery calcification in patients with rheumatoid arthritis. <i>Rheumatology International</i> , <b>2015</b> , 35, 1541-7	3.6	5
101	Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial". <i>Circulation</i> , <b>2015</b> , 132, e121-2	16.7	45
100	Coronary Artery Calcium Improves Risk Classification in Younger Populations. <i>JACC: Cardiovascular Imaging</i> , <b>2015</b> , 8, 1285-93	8.4	43
99	Soluble klotho and mortality: the Ludwigshafen Risk and Cardiovascular Health Study. <i>Atherosclerosis</i> , <b>2015</b> , 242, 483-9	3.1	25
98	Autoantibodies in dilated cardiomyopathy induce vascular endothelial growth factor expression in cardiomyocytes. <i>Biochemical and Biophysical Research Communications</i> , <b>2015</b> , 465, 119-24	3.4	3
97	Severe myocardial ischaemia after neonatal arterial switch operation. <i>European Heart Journal</i> , <b>2015</b> , 36, 3214	9.5	1
96	Target Organ Complications and Cardiovascular Events Associated With Masked Hypertension and White-Coat Hypertension: Analysis From the Dallas Heart Study. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 2159-2169	15.1	128
95	High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. <i>Nephrology Dialysis Transplantation</i> , <b>2015</b> , 30, 288-93	4.3	90
94	Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study. <i>Diabetes Therapy</i> , <b>2015</b> , 6, 635-642	3.6	15
93	Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. <i>Cardiovascular Diabetology</i> , <b>2015</b> , 14, 57	8.7	64
92	High-Risk Cardiovascular Patients: Clinical Features, Comorbidities, and Interconnecting Mechanisms. <i>Frontiers in Immunology</i> , <b>2015</b> , 6, 591	8.4	22
91	Heartbeat Cycle Length Detection by a Ballistocardiographic Sensor in Atrial Fibrillation and Sinus Rhythm. <i>BioMed Research International</i> , <b>2015</b> , 2015, 840356	3	18
90	Feasibility of bioelectrical impedance spectroscopy measurement before and after thoracentesis. <i>BioMed Research International</i> , <b>2015</b> , 2015, 810797	3	6
89	Predicting cardiovascular risk in type 2 diabetes: the heterogeneity challenges. <i>Current Cardiology Reports</i> , <b>2015</b> , 17, 607	4.2	21
88	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 232-42	59.2	1739
87	Relation of black race between high density lipoprotein cholesterol content, high density lipoprotein particles and coronary events (from the Dallas Heart Study). <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 890-4	3	29
86	Association between diabetes mellitus and angina after acute myocardial infarction: analysis of the TRIUMPH prospective cohort study. <i>European Journal of Preventive Cardiology</i> , <b>2015</b> , 22, 779-87	3.9	9

85	High prevalence of elevated haemoglobin A1C among adolescent blood donors: Results from a voluntary screening programme including 31,546 adolescents. <i>Diabetes and Vascular Disease Research</i> , <b>2015</b> , 12, 272-8	3.3	5
84	PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2015</b> , 81, 23-33	5.8	20
83	Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , <b>2015</b> , 38, 696-705	14.6	114
82	Patterns and predictors of intensive statin therapy among patients with diabetes mellitus after acute myocardial infarction. <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 1267-72	3	9
81	The relationship of body mass and fat distribution with incident hypertension: observations from the Dallas Heart Study. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 997-1002	15.1	154
80	Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. <i>Circulation</i> , <b>2014</b> , 130, 1579-88	16.7	479
79	Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies. <i>Clinical Therapeutics</i> , <b>2014</b> , 36, 1130-46	3.5	51
78	Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the United States: results from the National Cardiovascular Data Registry (NCDR). <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2014</b> , 7, 701-7	5.8	24
77	Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study. <i>Atherosclerosis</i> , <b>2014</b> , 237, 53-9	3.1	68
76	Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c. <i>American Heart Journal</i> , <b>2014</b> , 168, 457-465.e2	4.9	11
75	Prevalence of glucose abnormalities among patients presenting with an acute myocardial infarction. <i>American Heart Journal</i> , <b>2014</b> , 168, 466-470.e1	4.9	42
74	Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 1441-8	15.1	226
73	Type of $\beta$ -blocker use among patients with versus without diabetes after myocardial infarction. <i>American Heart Journal</i> , <b>2014</b> , 168, 273-279.e1	4.9	12
72	Homoarginine and cardiovascular outcome in the population-based Dallas Heart Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2014</b> , 34, 2501-7	9.4	57
71	GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering. <i>Diabetes</i> , <b>2014</b> , 63, 3221-9	0.9	119
70	Glycated hemoglobin in 14,850 adolescent blood donors: a pilot screening program. <i>Diabetes Care</i> , <b>2014</b> , 37, e3-4	14.6	5
69	Cardiovascular magnetic resonance profiling of coronary atherosclerosis: vessel wall remodelling and related myocardial blood flow alterations. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2014</b> , 15, 1400-10	4.1	6
68	The reliability of in-hospital diagnoses of diabetes mellitus in the setting of an acute myocardial infarction. <i>BMJ Open Diabetes Research and Care</i> , <b>2014</b> , 2, e000046	4.5	7

67	Is cardiorespiratory fitness a determinant of cardiomyopathy in the setting of type 2 diabetes?. <i>Diabetes and Vascular Disease Research</i> , <b>2014</b> , 11, 343-51	3.3	1
66	Electromagnetic interference with implantable cardioverter-defibrillators at power frequency: an in vivo study. <i>Circulation</i> , <b>2014</b> , 129, 441-50	16.7	27
65	Effects of ranolazine on quality of life among patients with diabetes mellitus and stable angina. <i>JAMA Internal Medicine</i> , <b>2014</b> , 174, 1403-5	11.5	13
64	Metformin in patients with type 2 diabetes and kidney disease: a systematic review. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 2668-75	27.4	355
63	Evaluation of a newly designed shirt-based ECG and breathing sensor for home-based training as part of cardiac rehabilitation for coronary artery disease. <i>European Journal of Preventive Cardiology</i> , <b>2014</b> , 21, 1332-40	3.9	14
62	Myocardial deformation imaging by two-dimensional speckle-tracking echocardiography for prediction of global and segmental functional changes after acute myocardial infarction: a comparison with late gadolinium enhancement cardiac magnetic resonance. <i>Journal of the American Society of Echocardiography</i> , <b>2014</b> , 27, 212-21	5.8	54
61	Novel insights into the mechanism of cell-based therapy after chronic myocardial infarction. <i>Discoveries</i> , <b>2014</b> , 2, e9	3.7	1
60	C-Peptide and its career from innocent bystander to active player in diabetic atherogenesis. <i>Current Atherosclerosis Reports</i> , <b>2013</b> , 15, 339	6	10
59	Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 1317-26	59.2	2459
58	Discordant effects of rosiglitazone on novel inflammatory biomarkers. <i>American Heart Journal</i> , <b>2013</b> , 165, 609-14	4.9	8
57	C-peptide levels are associated with mortality and cardiovascular mortality in patients undergoing angiography: the LURIC study. <i>Diabetes Care</i> , <b>2013</b> , 36, 708-14	14.6	28
56	2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. <i>European Heart Journal</i> , <b>2013</b> , 34, 2949-3003	9.5	3076
55	Glucagon-like peptide-1(9-36) inhibits chemokine-induced migration of human CD4-positive lymphocytes. <i>PLoS ONE</i> , <b>2013</b> , 8, e58445	3.7	8
54	Letter by McGuire and Aguilar regarding article, "Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the investigation of lipid level management to understand its impact in atherosclerotic events (ILLUMINATE) trial". <i>Circulation</i> , <b>2012</b> , 125, e427	16.7	
53	Commentary on Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis by Preiss et al. <i>Diabetes and Vascular Disease Research</i> , <b>2012</b> , 9, 78	3.3	1
52	Diabetes mellitus and trends in hospital survival after myocardial infarction, 1994 to 2006: data from the national registry of myocardial infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2012</b> , 5, 791-7	5.8	34
51	The effects of rosiglitazone on myocardial triglyceride content in patients with type 2 diabetes: a randomised, placebo-controlled trial. <i>Diabetes and Vascular Disease Research</i> , <b>2012</b> , 9, 131-7	3.3	14
50	Diabetes and the Cardiovascular System <b>2012</b> , 1392-1409		1

49	Variability of clopidogrel response in patients with type 2 diabetes mellitus. <i>Diabetes and Vascular Disease Research</i> , <b>2011</b> , 8, 245-53	3.3	27
48	Adiponectin and cardiovascular risk profile in patients with type 2 diabetes mellitus: parameters associated with adiponectin complex distribution. <i>Diabetes and Vascular Disease Research</i> , <b>2011</b> , 8, 190-4	3.3	22
47	Assessment of cardiac structure and function in patients without and with peripheral oedema during rosiglitazone treatment. <i>Diabetes and Vascular Disease Research</i> , <b>2011</b> , 8, 101-8	3.3	6
46	A commentary on Diabetic and non-diabetic patients with left main and/ or three-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents by Banning AP et al. <i>Diabetes and Vascular Disease Research</i> , <b>2011</b> , 8, 173	3.3	0
45	The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. <i>Diabetes and Vascular Disease Research</i> , <b>2010</b> , 7, 119-30	3.3	38
44	Diabetes and heart failure in patients with coronary disease: separating markers from mediators. <i>Diabetes Care</i> , <b>2010</b> , 33, 2120-2	14.6	5
43	Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 304, 2503-12	27.4	753
42	Associations of four circulating chemokines with multiple atherosclerosis phenotypes in a large population-based sample: results from the dallas heart study. <i>Journal of Interferon and Cytokine Research</i> , <b>2010</b> , 30, 339-47	3.5	24
41	Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function. <i>European Heart Journal</i> , <b>2010</b> , 31, 2262-70	9.5	22
40	Circulating lymphotoxin I receptor and atherosclerosis: observations from the Dallas Heart Study. <i>Atherosclerosis</i> , <b>2010</b> , 212, 601-6	3.1	14
39	Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes. <i>Cellular and Molecular Life Sciences</i> , <b>2010</b> , 67, 3549-55	10.3	27
38	The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial. <i>Calcified Tissue International</i> , <b>2010</b> , 86, 343-9	3.9	42
37	Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. <i>Diabetes Care</i> , <b>2009</b> , 32, 1218-20	14.6	77
36	Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. <i>Circulation</i> , <b>2009</b> , 119, 2032-9	16.7	120
35	Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. <i>Diabetes and Vascular Disease Research</i> , <b>2009</b> , 6, 7-14	3.3	62
34	Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment. <i>Expert Review of Cardiovascular Therapy</i> , <b>2009</b> , 7, 541-9	2.5	6
33	Differential associations between soluble cellular adhesion molecules and atherosclerosis in the Dallas Heart Study: a distinct role for soluble endothelial cell-selective adhesion molecule. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2009</b> , 29, 1684-90	9.4	37
32	The effect of rosiglitazone on integrated cardiovascular performance, cardiac structure, function and myocardial triglyceride: trial design and rationale. <i>Diabetes and Vascular Disease Research</i> , <b>2009</b> , 6, 43-50	3.3	11

31	Cardiovascular disease and type 2 diabetes mellitus: regulating glucose and regulating drugs. <i>Current Cardiology Reports</i> , <b>2009</b> , 11, 258-63	4.2	20
30	The association between peptidoglycan recognition protein-1 and coronary and peripheral atherosclerosis: Observations from the Dallas Heart Study. <i>Atherosclerosis</i> , <b>2009</b> , 203, 569-75	3.1	32
29	New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications. <i>Circulation</i> , <b>2008</b> , 117, 440-9	16.7	96
28	New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. <i>Circulation</i> , <b>2008</b> , 117, 574-84	16.7	154
27	Management of Coronary Artery Disease in Type 2 Diabetes Mellitus <b>2008</b> , 289-319		1
26	Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus. <i>Diabetes and Vascular Disease Research</i> , <b>2008</b> , 5, 59-66	3.3	34
25	Effects of the thiazolidinedione medications on micro- and macrovascular complications in patients with diabetes--update 2008. <i>Cardiovascular Drugs and Therapy</i> , <b>2008</b> , 22, 233-40	3.9	18
24	Cardiomyopathy in type 2 diabetes: update on pathophysiological mechanisms. <i>Herz</i> , <b>2008</b> , 33, 184-90	2.6	37
23	Metformin in heart failure. <i>Diabetes Care</i> , <b>2007</b> , 30, e129	14.6	45
22	The Editor's roundtable: diabetes mellitus and coronary heart disease. <i>American Journal of Cardiology</i> , <b>2006</b> , 98, 842-56	3	4
21	Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPAR gamma agonism. <i>Diabetes and Vascular Disease Research</i> , <b>2006</b> , 3, 65-71	3.3	34
20	Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. <i>Circulation</i> , <b>2006</b> , 113, 38-43	16.7	165
19	Increased cardiovascular risk associated with diabetes in Dallas County. <i>American Heart Journal</i> , <b>2006</b> , 151, 1087-93	4.9	6
18	Underuse of evidence-based treatment partly explains the worse clinical outcome in diabetic patients with acute coronary syndromes. <i>American Heart Journal</i> , <b>2006</b> , 152, 676-83	4.9	37
17	Urinary tract infection in patients with acute coronary syndrome: a potential systemic inflammatory connection. <i>American Heart Journal</i> , <b>2005</b> , 149, 1062-5	4.9	22
16	Management of diabetic dyslipidemia: need for reappraisal of the goals. <i>American Journal of Cardiovascular Drugs</i> , <b>2005</b> , 5, 83-91	4	7
15	Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. <i>European Heart Journal</i> , <b>2005</b> , 26, 1255-61	9.5	224
14	How aggressive should lipid lowering be among patients with acute coronary syndromes?. <i>Current Cardiology Reports</i> , <b>2005</b> , 7, 283-7	4.2	



13	Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?. <i>Diabetes and Vascular Disease Research</i> , <b>2005</b> , 2, 61-6	3.3	60
12	Diabetes mellitus and cardiovascular disease. Pandora's box has been opened. <i>Herz</i> , <b>2004</b> , 29, 456-62	2.6	12
11	Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. <i>American Heart Journal</i> , <b>2004</b> , 147, 246-52	4.9	60
10	Influence of the Angioplasty Revascularization Investigation National Heart, Lung, and Blood Institute Diabetic Clinical Alert on practice patterns: results from the National Cardiovascular Network Database. <i>Circulation</i> , <b>2003</b> , 107, 1864-70	16.7	21
9	Early statin initiation and outcomes in patients with acute coronary syndromes. <i>JAMA - Journal of the American Medical Association</i> , <b>2002</b> , 287, 3087-95	27.4	104
8	A 30-Year Follow-Up of the Dallas Bed Rest and Training Study. <i>Circulation</i> , <b>2001</b> , 104, 1358-1366	16.7	174
7	PPARalpha activators inhibit tissue factor expression and activity in human monocytes. <i>Circulation</i> , <b>2001</b> , 103, 213-9	16.7	161
6	A 30-Year Follow-Up of the Dallas Bed Rest and Training Study. <i>Circulation</i> , <b>2001</b> , 104, 1350-1357	16.7	138
5	PPARGamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARGamma as a potential mediator in vascular disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1999</b> , 19, 546-51	9.4	324
4	PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. <i>Circulation</i> , <b>1999</b> , 99, 3125-31	16.7	519
3	Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. <i>Circulation Research</i> , <b>1998</b> , 83, 1097-103	15.7	519
2	Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure. <i>ESC Heart Failure</i> ,	3.7	0
1	Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial. <i>Sleep and Breathing</i> ,	3.1	0